Trump pulls nomination for NASA administrator
The White House on Saturday said it will pull the nomination of tech entrepreneur Jared Isaacman as NASA administrator.
'It's essential that the next leader of NASA is in complete alignment with President Trump's America First agenda and a replacement will be announced directly by President Trump soon,' a White House spokesperson told The Hill.
The Senate was slated to vote on his nomination in the coming days.
Isaacman worked alongside tech billionaire Elon Musk at SpaceX to fund the company's first private spacewalk, and he was one of four astronauts aboard the Polaris Dawn flight this fall. He is also the founder and CEO of Shift4, a payment processing company.
President Trump announced Isaacman as his pick to lead the space administration in December, describing him as 'ideally suited to lead NASA into a bold new Era.'
Isaacman testified before the Senate in April as a part of the confirmation process. He advanced out of committee in a 19-9 vote.
Senate Majority Leader John Thune filed for cloture to vote on Isaacman's nomination on May 22.
It is not immediately clear why the president pulled his nomination on Saturday. The move was first reported by Semafor.
In early April, Isaacman contradicted Musk about space travel priorities. The commercial astronaut told senators he would focus on returning people to the moon, rather than Mars, which has been a priority of Musk's for some time.
'I'd like nothing more than to see … Americans walking on the moon,' he said during the Senate Commerce, Science and Transportation hearing.
This is the latest of a number of nominations Trump has pulled since returning to the White House. He pulled his original nominee for surgeon general earlier this month.
Rep. Elise Stefanik (R-N.Y.), who was nominated to serve as U.N. ambassador, was withdrawn from consideration in April amid tight margins in the GOP-controlled House. Trump eventually tapped Mike Waltz to be the country's U.N. ambassador after taking him out of the national security advisor role, now filled by Secretary of State Marco Rubio.
At least one Republican lawmaker has already opposed pulling Isaacman's nomination.
'Astronaut and successful businessman @RookIsaacman was a strong choice by President Trump to lead NASA. I was proud to introduce Jared at his hearing and strongly oppose efforts to derail his nomination,' first-term Sen. Tim Sheehy (R-Mont.) wrote in a Saturday post on social media platform X.
Earlier on Saturday, far-right influencer Laura Loomer had reported that 'deep state operatives' were attempting to prevent Isaacman from serving at the helm of NASA.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNET
17 minutes ago
- CNET
At $185, These Samsung Galaxy Buds 3 Pro Just Matched an Amazon All-Time Low
Samsung makes just about everything these days, including some of the best wireless earbuds on the market. The Samsung Galaxy Buds 3 Pro have all the features you'd expect from premium earbuds, and this is your chance to pick a pair up with a $65 discount. Thanks to this Amazon deal, you can currently get these incredible earbuds for just $185. That's the lowest price that we've seen Amazon sell these earbuds for, although it doesn't quite match a previous Woot deal that slashed them even further. That deal was for the international version, though, and you only got a 90-day warranty. Amazon's offer gets you the US version with a full two-year warranty, so that's worth keeping in mind. We can't vouch for how long this deal will last, which means you should definitely consider ordering soon. It's a limited-time deal, so it won't last forever. Hey, did you know? CNET Deals texts are free, easy and save you money. You'll definitely regret missing out if you're too late, too. These earbuds have a redesigned fit, which is said to offer a more comfortable listening experience. They're IPX7 water resistant, so you can use them when out in the rain and whatnot, and the noise cancellation features make them a perfect companion for loud offices and noisy commutes. In terms of battery life, Samsung says you can look forward to up to 8 hours, depending on whether you're using ANC or not, while the included charging case bumps that to 18 hours. Fast-charging tech ensures you can get a battery boost when needed, too. Because of all of this, this is easily one of the best wireless earbuds deals around right now. Why this deal matters Getting great features often means spending great sums of money, which is why we're always keen to share deals like this one. If you'd eyed these wireless earbuds in the past but balked at their $250 price tag, now's your chance to pick them up for less. Just make sure you do it before Amazon calls time on this deal.
Fast Company
17 minutes ago
- Fast Company
From immigration law to business success: Navigating the challenges for foreign business in the U.S.
As a U.S. business immigration attorney and founder of Grape Law Firm PLLC, I have worked with many foreign entrepreneurs who have achieved lasting success in the United States. Establishing and scaling a company here requires time, effort, and strategic planning to navigate a complex web of immigration regulations and compliance requirements. COMMON LEGAL HURDLES IN SECURING EMPLOYEE VISAS The primary challenge faced by businesspeople is securing a legal presence in the United States. This means obtaining the appropriate visa or status for both entrepreneurs and their essential personnel. However, the process of business immigration to the U.S. is often a challenging adventure. According to the 2024 CIS Ombudsman Annual Report, from initial market entry to business expansion—and even to permanent establishment—the complexities of business immigration affect entrepreneurs at every stage of their U.S. journey. They face significant challenges in documenting the viability of their enterprises to immigration officials while managing their immigration status to meet the changing needs of the business ecosystem. NAVIGATING VISA PATHWAYS FOR BUSINESS GROWTH As business immigration attorneys, one of our primary duties is to help our clients choose the most suitable visa for their business vision and goals. The selection of the appropriate visa is the foundation on which a successful application strategy is built and is an investment in the company's long-term growth. It is imperative for entrepreneurs to understand that various options exist for starting new businesses in the United States or expanding existing operations. Each visa category has its own distinct advantages and considerations based on differing business needs. For instance, the E‑1 Treaty Trader and the E‑2 Treaty Investor visas are viable options for entrepreneurs. These visa categories cater to foreign traders and investors who are citizens of treaty countries—countries that have treaty agreements with the U.S. Traders must engage in continuous trade with the United States, and the U.S. must be their primary trading partner. Conversely, investors must make substantial investments through new or existing enterprises. Both the E‑1 and E‑2 visas can support long-term, sustainable business ventures in the United States (each is valid for up to five years and can be extended indefinitely), provided that they spur economic progress in their respective industries and investment areas. Furthermore, the L‑1 Intracompany Transferee visa is an ideal choice for international companies planning to expand to the U.S. The L‑1 visa allows foreign companies to transfer their managerial or executive employees for new office openings, thereby facilitating the establishment of operations in the United States. However, a potential downside is that the L‑1 visa requires rigorous application preparation—a thorough case file must be compiled, followed by consistently detailed documentation of organizational development and business growth metrics, especially during the first three years of operations. A CASE IN POINT One case from our L‑1 visa practice perfectly illustrates these complexities. As a seasoned professional in the scaffolding industry, our client's initial L‑1 New Office visa application succeeded through careful preparation and a comprehensive five‑year business plan. However, the real challenges emerged during the extension phase. When she sought to extend her L‑1 visa with different legal counsel, she faced a rigorous Request for Evidence (RFE) from USCIS that scrutinized every aspect of her business operations. The RFE questioned not only the structure, but also its growth trajectory and staffing decisions—common challenges that many foreign businesses face in proving the legitimacy and sustainability of their operations. The industry's unique characteristics, including its project‑based nature and specialized staffing requirements, made it particularly challenging to conform to USCIS's traditional expectations for business development. Her case is a stark reminder for prospective entrepreneurs that experienced immigration counsel can provide needed guidance throughout the ups and downs of their U.S. immigration journey. Entrepreneurs must acknowledge that deciding on the right visa type is more than an entry ticket to the United States—a visa is the key to legal rights, business investments, and financial aspirations that influence one's life in the U.S. BUILDING A FOUNDATION FOR LONG-TERM SUCCESS The U.S. business immigration ecosystem is ever-changing and demands legal acumen in business planning—integrating proactive immigration solutions from the very beginning. To achieve lasting success, entrepreneurs need expert legal guidance to navigate the complex steps of immigration and adapt to any changes or updates in the immigration system. Beyond legal counsel, success often hinges on comprehensive preparation and strategic planning. Maintaining detailed business documentation from day one proves crucial for immigration success. Successful immigrant entrepreneurs often distinguish themselves through meticulous record-keeping of business transactions, employee contracts, and market analyses that demonstrate their enterprise's viability. Early strategic planning should include developing detailed business projections, establishing clear organizational structures, and creating systems for tracking achievements and metrics. These elements strengthen visa applications and create a foundation for sustainable growth. Networking within industry associations and chambers of commerce can provide valuable insights into immigration processes and business development. Furthermore, entrepreneurs who actively participate in their industry's ecosystem often find themselves better positioned to demonstrate their legitimacy to immigration authorities. This comprehensive approach, combining thorough documentation with strategic foresight, guarantees that immigration planning aligns with business goals while maintaining strict compliance with U.S. regulations. As we look to the future, business expansion into the United States and immigration to the country will only become more interlinked. In that regard, the aforementioned success story of our entrepreneur client is an excellent example—showcasing that viewing immigration not as a hurdle but as a strategic tool is essential for success. Always remember: proper planning, combined with expert guidance, can transform potential obstacles into opportunities for growth in the American market. The key to sustainable success lies in developing a nuanced understanding of how immigration pathways can support business objectives while ensuring compliance with regulatory requirements.
Forbes
18 minutes ago
- Forbes
Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This
A new survey report from the International Foundation of Employee Benefit Plans shows continued reluctance by United States employers to cover glucagon-like peptide-1 drugs for weight loss. Going forward, however, lower net costs may induce better coverage by employers. Makers of GLP-1s for obesity are offering an array of discounts, some to insurers, others directly to patients. The IFEBP first conducted the survey in Oct. 2023 and again in May 2024. In the latest survey released ten days ago, employers revealed that 55% of them provide coverage of GLP-1s for diabetes only, while only 36% provide coverage for both diabetes and weight loss. And of those employers currently offering GLP-1 drug coverage solely for diabetes, just 17% are considering reimbursement of drugs for weight loss. Broadly speaking, the survey responses demonstrate that a large number of employers are still unwilling to reimburse GLP-1s for obesity. The weight loss therapeutics activate the body's receptors for GLP-1 on its own or in combination with GIP. When released by the gut, these natural hormones increase insulin delivery, suppress appetite, slow stomach emptying and increase the feeling of fullness. Perhaps what's driving continued reluctance to cover these products for weight loss is the overall impact that GLP-1s have on employers' pharmacy budgets. GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims in the 2025 survey. In parts of the traditional health plans' market, we observe that some insurers are reconsidering their coverage of GLP-1s. Blue Cross Blue Shield, for example, just announced a reversal in its policy in which some plans offered coverage of GLP-1s for obesity. Starting in January 2026, BCBS will no longer cover these medicines for weight loss across the insurer's standard plans. At the same time, however, the large insurer Cigna announced it will begin capping out-of-pocket costs at $200 per month, starting next month, for patients using the obesity drugs Wegovy (semaglutide) and Zepbound (tirzepatide) through an add-on to its pharmacy benefit management plans. This is aimed at encouraging more employers to offer coverage of the drugs. It's unknown what the net cost to Cigna will be for the medicines. But presumably, the insurer has been able to reach a deal that's favorable financially, meaning a substantial reduction in net costs. It's possible in future that employers decide to revisit their coverage decisions if net costs decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and in conjunction with an appropriate dietary and exercise regimen. Also, the pharmaceutical firm Novo Nordisk announced last month a new partnership with CVS Caremark, the nation's largest pharmacy benefit manager, which grants coverage of Wegovy over its competitor Zepbound for customers who are insured for obesity medications. It's presumed that CVS was able to negotiate sizable rebates for Wegovy. CVS Caremark said that for insured patients, starting this July, Wegovy and Saxenda (liraglutide) will be the preferred GLP-1 medicines on its largest commercial formularies. This implies fewer access restrictions such as prior authorization, but also lower patient cost-sharing. It's unknown precisely what this means in terms of out-of-pocket costs for patients. But most patients with coverage for obesity drugs have monthly cost-sharing under $100. The arrangements reached by Cigna and CVS could help bring down net prices for employers for popular weight loss medicines. And at the same time, under the Inflation Reduction Act, the federal government is negotiating the prices of the GLP-1s Ozempic (semaglutide) and Wegovy. So-called maximum fair prices will be publicly posted in early 2026. These could reflect even steeper discounts. In addition to what payers are doing, Novo Nordisk is pursuing a direct-to-patient strategy to regain market share it has lost to drug maker Eli Lilly in the lucrative obesity drug market. Here, Novo Nordisk struck a deal in which CVS pharmacy will offer Wegovy for $499 a month for cash-paying customers who aren't insured for the medication. Since the Food and Drug Administration removed the active ingredients semaglutide and tirzepatide from its shortage list, the business model of selling directly at a considerable discount to the consumer has become popular for the two main manufacturers of obesity drugs. In 2024, Eli Lilly adopted a direct-to-consumer strategy for Zepbound, among other products, with its LillyDirect program. This service includes a DTC pharmacy and a referral network of in-person and telehealth clinicians. LillyDirect allows uninsured or underinsured individuals not on Medicaid or Medicare to purchase Zepbound product directly after obtaining the requisite prescription from their doctor. The firm recently extended the range of Zepbound products available through LillyDirect by adding high-dose vials at $499. Rival Novo Nordisk also launched a DTC option, NovoCare Pharmacy, two months ago. Patients not insured in the public sector who wish to have access to Wegovy can acquire the drug for an out-of-pocket cost of $499 per month, provided they have a prescription and make use of a designated specialty pharmacy. And, since the end of April, customers also pay a $499 monthly subscription when they obtain Wegovy from Ro and LifeMD, and $599 at Hims & Hers. While employers aren't yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future coverage decisions.
